HELP.US Helus Pharma Inc.
- Market cap
- USD 648M
- P/E
- -
- P/B
- 2.68x
- ROE
- -77.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is HELP.US undervalued?
Graham numberThe Graham number of Helus Pharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Helus Pharma Inc. fundamental analysis
No fundamental analysis for Helus Pharma Inc. yet.
Helus Pharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Helus Pharma Inc.
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine an…
Full company profileHelus Pharma Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Helus Pharma Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 864K | 168K | 251K | -18.1M | 472K | -44.7M | 0.00 |
| Gross Profit | - | - | - | - | -311K | -168K | -251K | -18.6M | -472K | -44.8M | -121K |
| Operating Income | -127K | -190K | -80.5K | -1.95M | -31.0M | -63.8M | -51.5M | -78.8M | -143M | -142M | -191M |
| EBITDA | -127K | -221K | -80.9K | -400.00 | -31.0M | -63.7M | -51.3M | -78.4M | -143M | -142M | -191M |
| Net Income | -127K | -221K | -101K | -1.94M | -32.2M | -67.6M | -47.5M | -78.1M | -113M | -147M | -186M |
| EPS | -0.35 | -0.69 | -0.28 | -1.48 | -12 | -15 | -9.73 | -3.90 | -5.59 | -4.23 | -3.56 |
| Balance Sheet | |||||||||||
| Total Assets | 443K | 456K | 408K | 1.71M | 92.1M | 84.1M | 53.9M | 302M | 259M | 252M | 259M |
| Total Liabilities | 150K | 15.9K | 13.7K | 263K | 5.99M | 7.91M | 5.66M | 10.1M | 21.4M | 19.4M | 17.5M |
| Shareholders' Equity | 293K | 440K | 395K | 1.45M | 86.1M | 76.2M | 48.2M | 292M | 237M | 232M | 242M |
| Cash & Short-term Investments | 433K | 433K | 314K | 1.55M | 64.0M | 53.6M | 16.6M | 209M | 135M | 158M | 166M |
| Total Debt | - | - | - | - | - | - | - | 291K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.81K | -237K | -83.8K | -1.38K | -19.0M | -45.2M | -47.4M | -68.9M | -101M | -132M | -145M |
| Capital Expenditure | 10.0K | 10.0K | 35.0K | 0.00 | 231K | 520K | 3.31M | 710K | 1.97M | 1.36M | 1.25M |
| Free Cash Flow | -7.19K | -247K | -119K | -1.38K | -19.3M | -45.7M | -50.7M | -69.6M | -103M | -134M | -146M |
| Ratios | |||||||||||
| ROE | -43.4% | -50.2% | -25.6% | -134.3% | -37.4% | -88.8% | -98.5% | -26.7% | -47.7% | -63.3% | -77.1% |
| ROA | -28.7% | -48.4% | -24.7% | -113.6% | -35.0% | -80.5% | -88.1% | -25.9% | -43.7% | -58.4% | -71.9% |
| Net Profit Margin | - | - | - | - | -3,729.2% | -40,314.1% | -18,919.2% | - | -23,956.0% | - | - |
| Debt to Equity | - | - | - | - | - | - | - | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Helus Pharma Inc. dividends
Helus Pharma Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:38 on Sep 19, 2024.
Who owns Helus Pharma Inc.
- Insiders 13.20%
- Institutions 39.00%
- Public & others 47.81%
- Shares outstanding 73.1M
- Free float 52.8M
Top funds holding HELP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SEB Läkemedelsfond A (SEK) | 885K | 1.21% | +15.84% | Sep 2026 |
| Biotech Growth Ord | 529K | 0.72% | -47.49% | Jul 2026 |
| AdvisorShares Psychedelics ETF | 360K | 0.49% | 0.00% | Oct 2026 |
| Royce Small-Cap Growth Svc | 281K | 0.38% | +21.12% | Sep 2026 |
| Royce Small-Cap Trust | 149K | 0.20% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 77.3K | 0.11% | +383.28% | Aug 2026 |
| Premier Miton Diversified GrB Inc | 72.7K | 0.10% | -3.96% | Sep 2026 |
| Fidelity Nasdaq Composite ETF | 31.1K | 0.04% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 29.6K | 0.04% | 0.00% | Oct 2026 |
| Premier Miton Global Leaders C Acc | 27.3K | 0.04% | 0.00% | Sep 2026 |
| JHVIT Health Sciences I | 21.8K | 0.03% | +0.27% | Sep 2026 |
| Premier Miton Diversified Bal Gr D Inc | 20.0K | 0.03% | -8.26% | Sep 2026 |
| EQ/T. Rowe Price Health Sciences IB | 15.4K | 0.02% | +10.79% | Sep 2026 |
| Premier Miton Diversified Dyn Gr D Inc | 14.0K | 0.02% | -4.76% | Sep 2026 |
| Premier Miton Diversified Cau Gr D Inc | 10.2K | 0.01% | -8.09% | Sep 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 10.0K | 0.01% | +1.92% | Oct 2026 |
| Arrow Opportunities Alternative Series F | 6.12K | 0.01% | 0.00% | Oct 2026 |
| China Universal Gbl YLBJ QDII CNH | 6.00K | 0.01% | 0.00% | Jun 2026 |
| NEI Long Short Equity F | 4.16K | 0.01% | +16.28% | Sep 2026 |
| T. Rowe Price Innovation Leaders ETF | 894.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding HELP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| VR Adviser, LLC | 3.85M | 5.27% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 3.27M | 4.48% | -14.65% | Jun 2026 |
| Adage Capital Partners Gp LLC | 3.06M | 4.19% | +337.14% | Jun 2026 |
| Millennium Management LLC | 2.63M | 3.60% | +8.95% | Jun 2026 |
| Rosalind Advisors, Inc. | 1.96M | 2.68% | +27.74% | Jun 2026 |
| Sphera Funds Management Ltd. | 1.62M | 2.22% | +64.20% | Jun 2026 |
| DCF Advisers, LLC | 1.43M | 1.96% | +107.37% | Jun 2026 |
| Sio Capital Management, LLC | 1.30M | 1.78% | 0.00% | Jun 2026 |
| Nan Fung Group Holdings Ltd | 987K | 1.35% | +114.61% | Jun 2026 |
| Boxer Capital Management, LLC | 790K | 1.08% | +23.44% | Jun 2026 |
| Logos Global Management LP | 750K | 1.03% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 621K | 0.85% | -29.22% | Jun 2026 |
| Dafna Capital Management LLC | 514K | 0.70% | +3.15% | Jun 2026 |
| Walleye Trading Advisors, LLC | 503K | 0.69% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 462K | 0.63% | -54.95% | Jun 2026 |
| Knott David M Jr | 370K | 0.51% | +5.71% | Jun 2026 |
| Bank of America Corp | 337K | 0.46% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 293K | 0.40% | +49.64% | Jun 2026 |
| Jane Street Group LLC | 281K | 0.38% | +164.13% | Jun 2026 |
| JPMorgan Chase & Co | 238K | 0.33% | +10,498.40% | Jun 2026 |
Helus Pharma Inc. company profile
- Company name
- Helus Pharma Inc.
- Ticker
- HELP.US
- ISIN
- CA23256X4075
- Exchange
- USA Stocks
- Listed since
- Sep 13, 2019
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 100
- Fiscal year end
- March
- Address
- 100 King Street West, Toronto, ON, Canada, M5X 1C9
- Phone
- 908 764 8385
- Website
- helus.com
About Helus Pharma Inc.
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
Helus Pharma Inc. management
10- Mr. Eric So L.L.B.Co-Founder & Chairman Emeritus · born 1976
- Mr. Paul GlavineCo-Founder & Director · born 1989
- Mr. Greg CaversChief Financial Officer · born 1971
- Mr. Aaron BartloneChief Operating Officer · born 1967
- Dr. Amir Inamdar FFPM, MBBSChief Medical Officer · born 1974
- Mr. Michael I. Halstead J.D.CEO & Director · born 1973
- Mr. John KanakisCo-Founder · born 1980
- Dr. Alex L. Nivorozhkin Ph.D.Chief Scientific Officer · born 1960
- Ms. Lori ChallengerChief Compliance, Ethics & Administrative Officer
- Mr. Gabriel FahelChief Legal Officer & Corporate Secretary · born 1976